BOSTON, April 14, 2019 — Gelesis, a biotechnology company developing first-in-class hydrogel therapeutics to treat obesity and other chronic diseases related to the gastrointestinal (GI) tract, today announced that the United States Food and…Original Article
Gelesis Granted FDA Clearance to Market Plenity – a New Prescription Aid in Weight Management
